Skip to content
value.today

Entera Bio Ltd.

ENTX
$543 Mmarket cap on Oct 30, 2026+2073.2% since Jan 2024
Compare
World rank
#12,196
Revenue
$0 M
For year ending December-2025
Net income
$-11 M
-28600.0% margin
SEC filing
Employees
22
As of December 31, 2025
SEC filing

Entera Bio Ltd. in brief

Entera Bio Ltd. is a listed company in the Biotechnology industry, based in Israel. Its market value was $543 M on 30 October 2026, which makes it the 12,196th largest listed company in the world and the 133rd largest in Israel on this site. In the year to December 2025 it had sales of $0 M and a net loss of $11 M. It employs about 22 people and Miranda Jayne Toledano is its chief executive. Its shares trade under the symbol ENTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Entera Bio Ltd.

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.

Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections can create a major treatment gap. From a technical standpoint, oral delivery of peptides and therapeutic proteins is challenging due to the enzymatic degradation within the gastrointestinal tract and poor absorption into the blood stream. We leverage our N-Tab® platform, which is designed to simultaneously stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream.

From the company's annual report filed with the US SEC: read the report

Entera Bio Ltd. timeline

3 events, 2015–2021
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 25 June 2018.
  5. 2021
  6. 💰
    Record revenue of $1 million
    FY2021, the highest of the 5 years on record.

Events of Entera Bio Ltd. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$151 M$301 M$452 M$602 M2020202120222023202420252026

World rank over time

▲ up 11,966 places since 2020
2020-01-01: #24198#24,19820202021-01-01: #23326#23,32620212022-01-07: #23894#23,89420222022-12-25: #31534#31,53420222023-07-30: #28957#28,95720232024-01-05: #28048#28,04820242026-03-08: #10781#10,78120262026-08-01: #11823#11,82320262026-10-14: #13286#13,28620262026-10-30: #12232#12,2322026

Rank in Israel: #314 (Jan 2020) · #342 (Jan 2021) · #327 (Jan 2022) · #416 (Dec 2022) · #396 (Jul 2023) · #381 (Jan 2024) · #38 (Mar 2026) · #134 (Aug 2026) · #146 (Oct 2026) · #133 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
13582.7×
Price / book
41.5×
Free cash flow yield
-1.4%
Net margin
-28600.0%
Operating margin
-28825.0%
Return on equity
-87.3%
Liabilities / assets
18.1%
Net debt
$-8M
Revenue growth
-77.8%
R&D / revenue
15000.0%
Revenue per employee
$2 K
Profit per employee
$-520 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue —, net income $-11M—FY17Fiscal year ending Dec 2018: revenue $1M, net income $-10M$1MFY18Fiscal year ending Dec 2020: revenue $0M, net income $-11M$0MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-12M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-13M$0MFY22Fiscal year ending Dec 2023: revenue —, net income $-9M—FY23Fiscal year ending Dec 2024: revenue $0M, net income $-10M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-11M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-77.8%$-12M$-11M-28600.0%
Dec 2024$0M—$-10M$-10M-5300.0%
Dec 2023——$-9M$-9M—
Dec 2022$0M-77.2%$-13M$-13M-10053.8%
Dec 2021$1M+58.3%$-12M$-12M-2138.6%
Dec 2020$0M-28.0%$-11M$-11M-3116.7%
Dec 2018$1M—$-11M$-10M-2060.0%
Dec 2017——$-11M$-11M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-7M$0M$-7M$0.25—
Dec 2024$-7M$0M$-7M$0.25—
Dec 2023$-7M$0M$-7M$0.31—
Dec 2022$-13M$0M$-13M$0.45—
Dec 2021$-9M$0M$-9M$0.47—
Dec 2020$-11M$0M$-11M$0.67—
Dec 2018$-10M$0M$-10M$1.31—
Dec 2017$-5M$0M$-5M$2.49—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-3M$0MMar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-7M—Jun ’26Three months to Sep 2026: revenue —, net income $-16M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Entera Bio Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-12 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$16 M
Total liabilities
$3 M
Total equity
$13 M

As of December-2025

Top 46 institutional investors in Entera Bio Ltd.#

As of Sep 30, 2026
46 institutions held 128.3 M shares (about 73.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 51.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Entera Bio Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
1BVF Inc/il17,052,893+14,627,893 (+603.21%)9.79%$50 MNov 16, 2026
2Vivo Capital, LLC12,254,901New7.04%$36 MNov 13, 2026
3TCG Crossover Management, LLC12,254,901New7.04%$36 MNov 16, 2026
4Spruce Street Capital LP11,213,455New6.44%$33 MNov 13, 2026
5Commodore Capital LP7,352,941New4.22%$21 MNov 16, 2026
6Seven Fleet Capital Management LP6,862,744+6,671,390 (+3486.41%)3.94%$20 MNov 16, 2026
7Siren, L.L.C.6,000,000+5,263,543 (+714.71%)3.45%$17 MNov 12, 2026
8Knoll Capital Management, LLC5,832,038-49,841 (-0.85%)3.35%$17 MNov 16, 2026
9Driehaus Capital Management LLC5,170,284New2.97%$15 MNov 16, 2026
10Venrock Adviser, LLC5,106,337New2.93%$15 MNov 16, 2026
11Ra Capital Management, L.P.4,901,960New2.81%$14 MNov 16, 2026
12Logos Global Management LP4,411,764New2.53%$13 MNov 16, 2026
13Catalio Capital Management, LP3,921,568New2.25%$11 MNov 16, 2026
14Perceptive Advisors LLC3,431,372New1.97%$10 MNov 16, 2026
15Nantahala Capital Management, LLC3,004,848New1.73%$9 MNov 13, 2026
16NEXTBio Capital Management LP2,923,937New1.68%$9 MNov 13, 2026
17Ameriprise Financial Inc2,682,285New1.54%$8 MNov 16, 2026
18ADAR1 Capital Management, LLC2,625,980New1.51%$8 MNov 16, 2026
19Adage Capital Partners GP, L.L.C.2,450,980New1.41%$7 MNov 16, 2026
20Deep Track Capital, LP2,450,980New1.41%$7 MNov 16, 2026
21Woodline Partners LP1,404,901New0.81%$4 MNov 16, 2026
22Foresite Capital Management VI LLC1,225,490New0.70%$4 MNov 16, 2026
23Affinity Asset Advisors, LLC934,412New0.54%$3 MNov 13, 2026
24SummitTX Capital, L.P.662,079New0.38%$2 MNov 16, 2026
25Parkman Healthcare Partners LLC298,791+24,294 (+8.85%)0.17%$1 MNov 16, 2026
Show all 46: investors 26 to 46
Institutional investors 26 to 46 in Entera Bio Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
26PNC Financial Services Group, Inc.273,0310 (0.00%)0.16%$1 MNov 6, 2026
27Diadema Partners LP245,098+221,838 (+953.73%)0.14%$1 MNov 16, 2026
28Marshall Wace, LLP210,747New0.12%$1 MNov 13, 2026
29Geode Capital Management, LLC178,259+148,351 (+496.02%)0.10%$1 MNov 6, 2026
30Schonfeld Strategic Advisors LLC162,694+103,823 (+176.36%)0.09%$0 MNov 16, 2026
31Jane Street Group, LLC157,857+140,526 (+810.84%)0.09%$0 MNov 12, 2026
32Renaissance Technologies LLC144,900-223,947 (-60.72%)0.08%$0 MNov 12, 2026
33Citadel Advisors LLC122,438+83,634 (+215.53%)0.07%$0 MNov 16, 2026
34HighTower Advisors, LLC77,382+2,809 (+3.77%)0.04%$0 MNov 10, 2026
35XTX Topco Ltd74,040+53,481 (+260.13%)0.04%$0 MNov 16, 2026
36Persistent Asset Partners Ltd61,060+55,179 (+938.26%)0.04%$0 MNov 13, 2026
37Signature Estate & Investment Advisors LLC47,3280 (0.00%)0.03%$0 MOct 13, 2026
38Jpmorgan Chase & Co41,896+1,013 (+2.48%)0.02%$0 MNov 12, 2026
39Gem Investment Advisors, LLC19,1350 (0.00%)0.01%$0 MNov 13, 2026
40UBS Group AG11,617-1,106 (-8.69%)0.01%$0 MNov 10, 2026
41Virtu Financial LLC10,259-26,662 (-72.21%)0.01%$0 MNov 17, 2026
42Morgan Stanley8,771+8,271 (+1654.20%)0.01%$0 MNov 13, 2026
43Caitong International Asset Management Co., Ltd823New0.00%$0 MOct 29, 2026
44Tower Research Capital LLC (TRC)65New0.00%$0 MNov 16, 2026
45Group One Trading LLC510 (0.00%)0.00%$0 MNov 10, 2026
46SBI Securities Co., Ltd.1New0.00%$0 MOct 22, 2026

Insider trading at Entera Bio Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$141 K
8 purchases, 5 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$141 K
open market only
Insiders on file
15
since
$83 K$0Dec 2023: bought $17 K (2 trades), sold $0 (0 trades)Dec 23Jan 2024: bought $15 K (2 trades), sold $0 (0 trades)Jan 24Dec 2025: bought $20 K (1 trades), sold $0 (0 trades)DecFeb 2026: bought $83 K (5 trades), sold $0 (0 trades)FebMar 2026: bought $38 K (2 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Entera Bio Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Geno J. GermanoDirectorGrant or award+25,014——65,014Form 4
filed Haya TaitelDirectorGrant or award+20,790——119,269Form 4
filed Steven D. RubinDirectorGrant or award+19,117——34,117Form 4
filed Yonatan MalcaDirectorGrant or award+22,815——100,231Form 4
filed Sean EllisDirectorGrant or award+20,034——208,132Form 4
filed Miranda Jayne ToledanoChief Executive Officer, DirectorGrant or award+347,567——774,142Form 4
filed Miranda Jayne ToledanoChief Executive Officer, DirectorGrant or award+72,993——847,135Form 4
filed Hillel GalitzerChief Operating OfficerGrant or award+72,993——163,566Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Entera Bio Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
7.1 M
15.3% of shares · 15.59 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-07-27 13:57 UTC, code LUDP, resumed 14:02 UTC
  • 2026-06-22 16:17 UTC, code LUDP, resumed 16:27 UTC

Fails to deliver

  • : 2,962 shares at $3.12
  • : 1,239 shares at $2.86
  • : 12,603 shares at $2.92
  • : 2,994 shares at $3.02
  • : 326 shares at $3.05

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Entera Bio Ltd. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median41.5×Price to book 41.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-1.4%Free cash flow is -1.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year0.25 vs 0.25Diluted EPS 0.25 in fiscal 2025 against 0.25 the year before (report's currency).
    • ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$11 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-108.0%-108.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities7.0×Current ratio 6.95 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year22.7%Diluted shares up 22.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Entera Bio Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Entera Bio Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.00.200.10.60.40.20.5——
Cost of revenue0.00.200.10.40.3r0.2———
Gross profit00.000.00.20.1————
Research and development6.04.54.55.86.86.4r7.28.52.82.6
Selling, general and administrative0.40.3————————
General and administrative5.55.14.47.35.74.9————
Operating expenses129.68.9131211————
Operating income−12−9.6−8.9−13−12−11r−11−11−11−5.4
Other non-operating income (expense)0.10.10.00.1−0.0−0.0————
Income before tax−11−9.5−8.9−13−12−11r−11−10——
Income tax00.00.00.1−0.10.0————
Net income including minority interests—————−10.0−11−10−11−1.2
Net income attributable to shareholders−11−9.5−8.9−13−12−11————
Earnings per share, basic0.250.250.310.450.470.67r0.891.302.490.27
Earnings per share, diluted0.250.250.310.450.470.67r0.891.312.490.78
Shares, weighted average (basic)463829292618128.04.54.5
Shares, weighted average (diluted)463829292618r128.04.56.8
Balance sheet
Cash and cash equivalents7.18.71112258.615r7.5124.2
Receivables00.100.20.20.30.30.7——
Other current assets0.1r0.2r0.2r0.3r0.30.3r0.10.10.2—
Current assets159.01113259.1161212—
Property, plant and equipment0.10.10.10.10.20.20.20.20.2—
Right-of-use (leased) assets0.50.30.40.10.20.4r0.30.2——
Other intangible assets—————0.60.60.70.7—
Non-current assets0.70.40.50.30.70.6r1.10.90.9—
Total assets169.41213269.7r171313—
Accounts payable0.40.10.10.00.20.2r1.41.11.4—
Current liabilities2.21.21.11.33.21.8r4.63.2r2.0—
Long-term debt————————3.9—
Lease liabilities (non-current)0.30.10.300.10.20.1———
Non-current liabilities0.70.10.30.00.30.4r0.20.1r43—
Total liabilities2.91.31.41.43.42.2r4.83.245—
Retained earnings−125−114−104−95−82−70r−63−52−42—
Shareholders' equity138.11012237.514———
Total equity—————6.71210−32−25
Total liabilities and equity169.41213269.7r171313—
Shares outstanding46393529292118114.54.5
Cash-flow statement
Depreciation and amortization—————0.20.20.10.00.0
Share-based compensation2.82.61.72.21.90.91.51.24.91.5
Cash from operating activities−7.4−6.8−7.3−12−9.1−11r−8.9−9.8−4.5−3.1
Capital expenditure−0.1−0.0−0.0−0.0−0.0−0.1−0.0−0.1−0.1−0.0
Cash from investing activities−0.1−0.0−0.0−0.1−0.0−0.1r3.9−4.11.0−1.1
Debt issued—————————7.2
Debt repaid————————−1.0—
Shares issued6.34.00.00223.2——12—
Cash from financing activities144.56.00.0254.1r139.6117.2
Exchange-rate effect on cash−0.00————————
Change in cash6.2−2.3−1.3−1316−6.6r7.7−4.27.63.0
Report10-K10-K10-K10-K10-K10-K20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Entera Bio Ltd. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Entera Bio Ltd.: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters—
🇺🇸 USA1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Entera Bio Ltd.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.5 M
Miranda Toledano
Other top executives, average
$518 K
the CEO earned 2.9× this
$100 invested is now
$223
Entera Bio Ltd.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Miranda Toledano$1.5 M$1.4 M$518 K$223
2024Miranda Jayne Toledano$1.1 M$2.2 M$485 K$212

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Entera Bio Ltd.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 6 · Material agreement 4 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 10

Entera Bio Ltd.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K/A
Results announced8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Entera Bio Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2026$275 MPrivate placement after listing$250 million to $1 billion53equity, optionsSEC
Dec 2023$7 MPrivate placement after listing$2 to $10 million52equity, optionsSEC
Dec 2019$14 MPrivate placement after listing$10 to $50 million52equity, optionsSEC
Oct 2017$2 MNo. 1$2 to $10 million30equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Discuss Entera Bio Ltd.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 6 November 2026automatic update · Nov 6, 2026

    Entera Bio Ltd. announced results on 6 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $16 million.

How Entera Bio Ltd. compares in Biotechnology

  • Market cap$543 M · higher than 59% of 726
  • Revenue$0 M · higher than 14% of 647
  • Revenue growth-77.8% · higher than 7% of 438
  • Price / book41.5× · lower than 4% of 534
  • FCF yield-1.4% · higher than 83% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Entera Bio Ltd.🇮🇱$543 M——-77.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Entera Bio Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Entera Bio Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Entera Bio Ltd.? Suggest a correction